Cantor Fitzgerald reissued their positive rating on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note published on Thursday, The Fly reports.
A number of other research firms have also recently commented on TXMD. ValuEngine raised shares of TherapeuticsMD from a hold rating to a buy rating in a research report on Thursday, February 28th. BidaskClub raised shares of TherapeuticsMD from a sell rating to a hold rating in a research report on Tuesday, February 5th. Zacks Investment Research cut shares of TherapeuticsMD from a hold rating to a sell rating in a research report on Thursday, February 28th. reaffirmed a buy rating and issued a $14.00 target price on shares of TherapeuticsMD in a research report on Tuesday, February 12th. Finally, Oppenheimer reaffirmed a buy rating on shares of TherapeuticsMD in a research report on Tuesday, March 19th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of $14.45.
Shares of TXMD opened at $4.23 on Thursday. The company has a quick ratio of 4.47, a current ratio of 4.55 and a debt-to-equity ratio of 0.75. TherapeuticsMD has a 12-month low of $3.51 and a 12-month high of $7.66. The stock has a market capitalization of $1.02 billion, a P/E ratio of -7.17 and a beta of 2.06.
In other TherapeuticsMD news, Director Jules A. Musing sold 17,400 shares of the company’s stock in a transaction dated Wednesday, February 27th. The shares were sold at an average price of $5.80, for a total value of $100,920.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at $29,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 22.85% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC acquired a new position in TherapeuticsMD in the first quarter valued at about $249,000. Tibra Equities Europe Ltd acquired a new stake in shares of TherapeuticsMD during the first quarter worth about $817,000. Geode Capital Management LLC lifted its position in shares of TherapeuticsMD by 9.0% during the fourth quarter. Geode Capital Management LLC now owns 2,206,185 shares of the company’s stock worth $8,405,000 after purchasing an additional 183,048 shares in the last quarter. Norges Bank acquired a new stake in shares of TherapeuticsMD during the fourth quarter worth about $2,729,000. Finally, FMR LLC lifted its position in shares of TherapeuticsMD by 50.1% during the fourth quarter. FMR LLC now owns 18,088,341 shares of the company’s stock worth $68,917,000 after purchasing an additional 6,038,353 shares in the last quarter. 77.39% of the stock is currently owned by institutional investors.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Further Reading: What are the advantages of the Stochastic Momentum Index?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.